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parameters (e.g. rate of HAQ progression and baseline demographics) and assump-
tions (e.g. extent to which HAQ improvement diminishes on withdrawal from ther-
apy) are influential on the ICER. CONCLUSIONS: Our results indicate that Adali-
mumab, and also Etanercept, have the highest probability of being the most cost-
effective of the biologic strategies at typical values of WTP.
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OBJECTIVES: Although osteoporosis is well recognized as a risk factor for fractures
among postmenopausal women, there has been no appraisal of the economic im-
pact of anti-osteoporotic therapy in Korea. Cost-effectiveness and cost-utility anal-
yses of anti-osteoporotic therapy were performed from the Korea National Health
Insurer perspective METHODS: Markov cohort simulation was performed to com-
pare the impact of bisphosphonates therapy to placebo in terms of incremental
cost per fracture averted and incremental cost per quality-adjusted life year (QALY)
saved for a hypothetical cohort of 1,000 Korean elderly osteoporotic women.
Within each health intervention strategy, all individuals began the simulation in
the health state ‘healthy’ and moved among the 5 health states (healthy, healthy
post-vertebral fracture, healthy post-hip fracture, healthy post 2nd hip fracture, and death)
in yearly cycles until 99 years old or death. To obtain transition probability of having
fractures, age-specific incidence rate of fracture was derived from published literature.
The combined weighted mean efficacy of alendronate and risedronate , which are the
most widely used bisphosphonates in Korea, for reducing the risk of fracture was
calculated from efficacy measures drawn from a meta-analysis. Data regarding
utilities and costs of fractures were derived from published local sources.RESULTS:
In the base case, the estimated incremental cost-utility ratio (ICUR) was 35 million
Korean won (KRW) per quality-adjusted life-year (QALY) gained, and the estimated
incremental cost-effectiveness ratio was 15 million KRW per fracture averted. Ac-
cording to the sensitivity analysis results, the efficacy of bisphosphonates therapy
and the starting age of therapy had the biggest impact on the estimated ICUR.
CONCLUSIONS: Based on this analysis, bisphosphonates therapy is likely to be
cost-effective for the primary prevention of fracture among Korean elderly women
at a willingness-to-pay threshold of 40-60 million KRW (i.e., 2-3 times per-capita
gross domestic product) per QALY.
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OBJECTIVES: To evaluate the cost per ACR70 response rate of biologic disease-
modifying antirheumatic drugs (bDMARDs) in the treatment of patients with active
rheumatoid arthritis (RA) and inadequate response to traditional DMARDs
(DMARD-IR) from the perspective of the Portuguese public health service.
METHODS: A systematic literature review considering randomized, controlled,
double-blind, multicentric clinical trials that evaluated the efficacy of bDMARDs’ -
abatacept, adalimumab, etanercept, golimumab, infliximab and tocilizumab – in
combination with DMARDs in the treatment of patients with active RA and
DMARD-IR, was performed, and 22 clinical trials were identified. ACR70 response
rates in each trial were adjusted for a placebo reference rate, which incorporated
the placebo response rates observed in all the trials. Odds ratio between the pla-
cebo group and the placebo reference group was thus assumed to reflect the base-
line differences between each trial results and a global reference population. Meta-
analyses were then performed to obtain the adjusted ACR70 response rate for each
bDMARD. The analysis considered drug and administration costs, obtained from
Portuguese official sources, and a 6-month time horizon. RESULTS: The highest
adjusted ACR70 response rate was obtained with tocilizumab (31,3%) followed by
adalimumab (25%), golimumab (20,2%), infliximab (19,6%), etanercept (15,5%) and
abatacept (11,7%), which is in line with earlier published evidence. Treatment costs
were lower with infliximab (4.577€) followed by tocilizumab (5.366€), etanercept
(5.695€), golimumab (5.921€), adalimumab (6104€) and abatacept (7.764€). The low-
est mean treatment cost to achieve an ACR70 response was obtained with tocili-
zumab (17.143€) followed by infliximab (23.354€), adalimumab (24.414€), goli-
mumab (29.311€), etanercept (36.743€) and abatacept (66.356€). CONCLUSIONS:
Due to the higher predicted ACR70 response rate, using tocilizumab for the treat-
ment of adult RA DMARD-IR patients provides the lowest cost per 70% or higher
improvement in disease activity among bDMARDs.
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Venous thromboembolism (VTE) is a disease that includes both deep vein throm-
bosis (DVT) and pulmonary embolism (PE), representing a serious public health
concern due to its impact in morbidity and mortality, and higher costs. Without
any prophylaxis, the incidence of DVT in patients undergoing total knee replace-
ment surgery (TKRS) ranges 40-84%. OBJECTIVES: To assess the cost and effective-
ness of bemiparin and enoxaparin when used as prophylaxis for VTE in TKRS under
the perspective of the Mexican public health care system. METHODS: We con-
ducted an economic evaluation based in a decision tree. Competing interventions
were bemiparin 3.500 IU/d started 6 hours after surgery and enoxaparin 40 mg/d
started 12 hours before surgery, for 102 days. Time horizon covered prophylaxis
plus 6 weeks of follow-up after hospital discharge. Probabilities of VTE events
(proximal DVT and symptomatic PE) as well as complications (major/minor bleed-
ing and thrombocytopenia) were derived from a head-to-head randomized double-
blind clinical trial. Only direct medical costs, comprising the acquisition cost of
agents used as prophylaxis besides the medical attention of VTE events and com-
plications, were analyzed. Resource use was determined by a Delphi Panel and
published literature. Unit costs were gathered from The Mexican Social Security
Institute (IMSS). Diagnosis-related groups’ costs at IMSS were also included into the
analysis. All costs are expressed in 2011 Mexican pesos (MXN). The efficacy mea-
sure was the proportion of patients free of VTE events. RESULTS: Selected VTE
events were 70% lower with bemiparin than with enoxaparin (18 vs. 60 cases per
1000 patients). Bemiparin also provided savings of 3521 MXN (47.4%) per patient
when used instead of enoxaparin for prophylaxis of VTE in TKRS. Model was
robust. CONCLUSIONS: Bemiparin is a dominant (both less costly and more effec-
tive) intervention over enoxaparin for the prophylaxis for VTE in TKRS in the Mex-
ican public health care setting.
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OBJECTIVES: RA prevalence is 0.5% in Turkey. This rate, as those in other Medi-
terranean countries, is lower compared with other European countries,. Initial RA
treatment consists of using Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Following inadequate response to DMARDs patients may switch to biologic treat-
ment options including tumour-necrosis factor (TNF) inhibitors. Tocilizumab is
approved by Turkish Ministry of Health for the treatment of active RA patients who
have responded inadequately to previous anti-TNF therapy. The study aimed to
assess tocilizumab’s cost-effectiveness for treatment of active RA patients with
inadequate response to previous anti-TNF treatment in Turkey. METHODS: Cost-
effectiveness analysis performed from payer’s perspective considered direct med-
ical costs. Markov model was used to compare two treatment sequences:1) tocili-
zumab, rituximab, abatacept, leflunomide, cyclosporin, palliative care, and 2)
rituximab, abatacept, leflunomide, cyclosporin, palliative care. Time horizon was
end of life. Patient characteristics were based on phase III study data (RADIATE).
Mixed treatment comparison was used to adjust ACR response rates for each of the
treatments in both sequences. Relationship between HAQ-DI scores and EuroQol
(EQ-5D) utilities was modeled by using patient data from trials. Resource use was
estimated based on expert opinion. Treatment costs (drug acquisition, administra-
tion, monitoring) were obtained from official lists published by Turkish Ministry of
Health and public payer. Costs and effects were not discounted. Results were tested
using deterministic and probabilistic sensitivity analyses. RESULTS: Treatment
sequence initiated with tocilizumab resulted in 0,528 life years gained and 1,873
QALYs more than alternative sequence at an additional cost of TRY63.788. ICER
was TRY34.052/QALY, which is below the threshold (TRY53.000/QALY based on
WHO recommendation). Sensitivity analyses confirmed that ICER was below the
threshold in 97% of the samples. CONCLUSIONS: Treatment initiated with tocili-
zumab in active RA patients with inadequate response to previous anti-TNF treat-
ment is cost-effective compared to alternative treatment sequence in Turkey.
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OBJECTIVES: To evaluate the cost-effectiveness of denosumab compared to alen-
dronate, zoledronic acid and no active osteoporosis treatment, for the treatment of
post-menopausal osteoporosis (PMO) in elderly women aged 75 years and older in
Sweden. METHODS: A previously developed Markov cohort model was updated
and used to estimate costs and effects, i.e. reductions in fracture occurrence, of
denosumab vs. comparators in that elderly population. The model was populated
with Swedish data on cost and fracture risks, and available clinical trial evidence
on treatment fracture risk reduction for hip, vertebral and other fractures in an
elderly population aged 75 years or older, where available. A life-time perspective
was applied and analysis were performed both with the assumption that all pa-
tients stay on therapy for all 5 years and that some patients drop out of treatment
over time (i.e. adjusting for imperfect treatment persistence). RESULTS: The base-
case analysis showed that denosumab was cost-saving and more effective (i.e.
dominant) versus all three comparators. The cost savings without adjustment for
imperfect treatment persistence amounted to €4,500, €4,800 and €500 per patient,
compared to no treatment, zoledronate and alendronate, respectively. Hip fracture
is the most common fracture type in the elderly population, and denosumab treat-
ment for 5 years avoided 140, 100 and 55 hip fractures per 1,000 treated patients,
compared to no treatment, zoledronate and alendronate, respectively. Univariate
and probabilistic sensitivity analyses showed that results were stable; denosumab
dominated all comparators if consequences of imperfect treatment persistence
were included or if comparator treatment costs were set to zero. CONCLUSIONS:
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